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Abstract
Approximately thirty percent of patients with gastric 
cancer undergo an avoidable lymph node dissection 
with a higher rate of postoperative complication. 
Comparing the D1 and D2 dissections, it was found that 
there is a significant difference in morbidity, favoured 
D1 dissection without any difference in overall survival. 
Subgroup analysis of patients with T3 tumor shows 
a survival difference favoring D2 lymphadenectomy, 
and there is a better gastric cancer-related death and 
non-statistically significant improvement of survival for 
node-positive disease in patients with D2 dissection. 
However, the extended lymphadenectomy could improve 
stage-specific survival owing to the stage migration 
phenomenon. The deployment of centralization and 
application of national guidelines could improve the 
surgical outcomes. The Japanese and European guide-
lines enclose the D2 lymphadenectomy as the gold 
standard in R0 resection. In the individualized, stage-
adapted gastric cancer surgery the Maruyama computer 
program (MCP) can estimate lymph node involvement 
preoperatively with high accuracy and in addition the 
Maruyama Index less than 5 has a better impact on 
survival, than D-level guided surgery. For these reasons, 
the preoperative application of MCP is recommended 
routinely, with an aim to perform “low Maruyama Index 
surgery”. The sentinel lymph node biopsy (SNB) may 
decrease the number of redundant lymphadenectomy 
intraoperatively with a high detection rate (93.7%) 
and an accuracy of 92%. More accurate stage-adapted 
surgery could be performed using the MCP and SNB in 
parallel fashion in gastric cancer.
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dissection without any difference in overall survival. 
The implementation of centralization and application 
of national guidelines could improve the surgical 
outcomes. More accurate stage-adapted surgery could 
be performed using the Maruyama computer program 
and sentinel lymph node biopsy in parallel fashion in 
gastric cancer.
Tóth D, Plósz J, Török M. Clinical significance of lympha-
denectomy in patients with gastric cancer. World J Gastrointest 
Oncol 2016; 8(2): 136-146  Available from: URL: http://www.
wjgnet.com/1948-5204/full/v8/i2/136.htm  DOI: http://dx.doi.
org/10.4251/wjgo.v8.i2.136
INTRODUCTION
In most cases, modern, optimal treatment of patients 
with different neoplasms can be achieved with a stage 
adapted, combined modality therapy according to inter­
national protocols. In case of solid tumors, the lymph 
node (LN) involvement and its exact number is the most 
important prognostic factor. Adjuvant chemotherapy, 
as well as the oncological outcome is terminated by the 
tumor­node­metastasis stage. Preoperative imaging 
techniques provide a much more accurate determination 
of the T and M stage than that of the N stage. The 
correct status of LN metastases can be obtained only 
by histology following an optimally extended node 
dissection. The removal of further LNs on the other hand, 
increases operative time, the rate of complications, and if 
negative may be considered unnecessary.
Almost three hundred thousand patients with gastric 
adenocarcinoma do not have LN metastasis in the one 
million new cases each year[1,2]. The depth of tumor 
invasion[3,4], the metastatic LN status and R0 resection 
are the most important independent prognostic factors 
for overall and disease free survival (OS, DFS)[5­7]. 
Moreover, a lot of study proved that LN metastasis is an 
independent risk factor for local recurrence as well as the 
time interval between radical gastrectomy and hepatic 
metastasis in patients after R0 resection[8­10].
The aim of this review is to report the latest issues 
from 2014 according to lymphadenectomy in gastric 
cancer and compare these results with earlier studies. 
LN INVOLVEMENT
Successful estimation of LN involvement may help to 
define which patients would or would not benefit from 
an extended LN dissection in association with gastrec­
tomy[11]. However, preoperative diagnostic tools have a 
low sensitivity and specificity for defining these patient 
subpopulations. Sensitivity, specificity and accuracy of 
spiral computer tomography for detection of pathologic 
LN involvement are 73.1%, 50.0% and 84.2%, respec­
tively[11,12]. Endoscopic ultrasonography has an accuracy 
of 68.6%, with a sensitivity and specificity of 66.7% 
and 73.7%, respectively[11,13]. The real problem of these 
imaging procedures is that exclusion of endoscopic 
ultrasonography, only the size of the LNs is taken into 
account. 
In association with T stage, LN involvement can be 
found in 15% of patients with carcinoma confined to 
the mucosa, whereas LN metastases were detected in 
23.4%, 48.2%, and 69.8% of patients with carcinoma 
invading the submucosa, muscularis propria and serous 
layer, respectively[14] Gertler et al[15] showed that not only 
infiltration of the submucosa but also lymphatic vessel 
invasion, multifocal tumor growth, younger patient age 
and poor tumor differentiation were associated with 
nodal disease. Besides T stage, LN involvement can also 
be influenced by tumor size. The overall accuracy of 
tumor size for preoperative N staging was 82.13%[16]. 
The incidence of LN metastasis in patients with a cancer 
size of 3­5 cm is 64.9%, 80% in patients with a cancer 
size of 5­7 cm and 84.3% in patients with a cancer size 
of > 7 cm[14]. Additionally, early gastric cancer (EGC) has 
nodal metastases in 38.9% in poorly differentiated or 
undifferentiated types of tumor, in 41.7% with Lauren 
diffuse type and in 33.3% with a size larger than 3 cm[17]. 
Yang et al[18] found that venous invasion, submucosal 
invasion or antral tumor location were independent pre­
dictors for LN metastasis in multivariate analysis. The 
rates of LN metastasis were 1.1% for patients with one 
or no predictor and 17.8% for those with two or more 
predictors[18].
While the prognostic significance of macrometastasis 
in the LNs is obvious, the role of lymphovascular invasion 
(LVI) or micrometastasis (MM) is controversial. Lee et 
al[19] confirmed that the recurrence-free survival is lower 
in N0/LVI(+) patients than in N0/LVI(­) patients, however 
they did not find any effect of LVI+ on overall survival. 
The incidence of LN MM is lower than 10% in patients 
with node negative EGC[20] but it is higher in histologically 
diffuse type tumors[21]. The presence of MM influenced 
DFS, although the OS analysis revealed no significant 
difference between MM­positive and MM­negative 
patients[19]. The reverse transcriptase polymerase chain 
reaction proved to be the most sensitive method in the 
detection of MM[22]. 
Meanwhile, a multivariate survival analysis con­
cluded that the number of examined LN (eLN) was an 
independent predictor of overall survival of patients 
with node­negative gastric cancer. According to the cut­
point analysis, T2­T4 patients with 11­15 eLN had a 
significantly longer mean OS than those with 4-10 eLN 
or 1-3 eLN. Patients with ≤ 15 eLN were more likely to 
experience locoregional and peritoneal recurrence than 
those with > 15 eLN[23]. However, this trend was not 
observed when the number of examined LN exceeded 
30[24].
These results are potentially associated with the 
elimination of MM in negative LNs[25]. Based on these 
findings, LVI and MM should be considered in posto­
perative management of gastric cancer[19].
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LYMPHADENECTOMY
D1 vs D2 lymphadenectomy
The adequate extension of lymphadenectomy differs 
significantly between East Asian and Western countries. 
Extended lymphadenectomy (D2) is the standard of 
care in Japan and South Korea, while for example, the 
majority of United States patients receive at most a 
limited lymphadenectomy (D1)[26,27]. This controversy 
may originate from different factors. First, the incidence 
of gastric cancer is significantly higher in Asia than in 
European Union, or in the United States[27,28].
Second, centralization of treatment has not yet been 
solved in the latter regions; 80% of Medicare patients 
with gastric cancer in the United States go through sur­
gery in centers performing less than 20 procedures per 
year[29] and there is a significant number of low-volume 
surgeons performing less than two cases annually[30,31]. 
Table 1 shows the primary and revised results of 
prospective randomized trials (RCT) comparing D1 to 
D2 lymphadenectomy in association with postoperative 
morbidity, mortality, frequency of splenectomy and 
pancreatectomy and long term oncological outcomes 
such as relapse risk and overall survival (OS). The three 
earliest studies found a higher morbidity and mortality 
rate following extended LN dissection of patients with 
gastric cancer when compared to those undergoing D1 
dissection only[11,32­34]. These higher rates were related 
mostly to splenectomy and pancreatectomy. Although 
Dent et al[32] did not perform resection of these organs, 
this study should be evaluated with reservations because 
of the small series size. Furthermore, limited surgical 
experience could explain these results. The quality 
control of lymphadenectomy was inadequate, as the 
non­compliance rate (absence of LNs from more than 
two LN stations that were supposed to be harvested) 
was 51% in the D2 group in the Dutch trial[34,35] and, in 
the extended group of the British trial, the dissection of 
LN station no.7 was 63.5%, and was less than 50% in 
station no.8 and no.9[36]. 
Moreover, extended LN dissection did not have any 
effect on oncological outcomes. The relapse risk and 
survival were similar in these studies. Only the revision 
of the Dutch trial showed better survival in advanced 
disease in the D2 group, after 11­year follow­up[37]. The 
15­year follow­up results revealed that cancer­related 
death rates were lower (37% vs 48%) with a lower rate 
of local recurrence in the D2 lymphadenectomy group 
(Table 1)[38]. Subgroup analysis of this trial demonstrated 
significantly higher survival for females (35% vs 21%) 
and in stage Ⅱ disease (33% vs 15%) in the D2 arm. 
The 15­year survival in patients without pancreatico­
splenectomy was significantly higher with D2 than D1 
dissection (35% vs 22%)[38].
The two latest randomized trials from the 21st century 
did not present significant differences in postoperative 
mortality between the D1 and D2 group[35,39]. The mor­
bidity rate was higher with D2 lymphadenectomy in the 
Taiwanese trial (which compared D1 to D3 dissection; 
however their D3 lymphadenectomy is similar to the 
current definition of D2 dissection). The Italian study did 
not show this difference and proved that D2 dissection 
could be performed safely without splenectomy and 
distal pancreatectomy, with comparable mortality and 
morbidity to those with D1 dissection in specialized 
centers[39,40]. These rates are comparable to the Japan 
Clinical Oncology Group (JCOG) 9501 trial and the na­
tionwide Japanese registry where the mortality was 
less than 2% after D2 dissection[41,42]. Neither did the 
latter study find any survival benefit from the extended 
lymphadenectomy[43]. Subgroup analyses showed a 
5-year disease-specific survival benefit for patients with 
pathological tumor 1 (pT1) disease in the D1 group (9% 
vs 83% for the D2 group; P = 0.015), and for patients 
with pT2­4 status and positive LNs in the D2 group (59% 
vs 38% for the D1 group; P = 0.055). However, the 
non­compliance rate was 33.6%[43]. It was concluded 
that the contamination (over­extensive nodal dissection) 
(18%) and the higher rate of stage IA disease in the D1 
group and of stage Ⅳ in the D2 arm, apparently nullified 
the effect of correct extended dissection[41,43]. The other 
randomized trial from Taiwan proved a better (P = 0.041) 
survival with D2 dissection[44].
The results of these recent studies call attention to 
the importance of the learning curve and the necessity 
of standardized procedures with routine preservation of 
the spleen and pancreas in experienced centers
[40]
. 
Besides the RCT, the latest meta­analysis found 
significant differences in morbidity, anastomotic leakage, 
pancreatic leakage, reoperation rates, wound infection, 
pulmonary complications and postoperative mortality, 
all of which favoured D1 dissection. The conclusion 
was that there is no difference in OS when comparing 
the D1 and D2 arm. Subgroup analysis of patients 
Ref. Morbidity (%) Mortality (%) Splenectomy (%) Pancreatectomy (%) RR (%) OS (%)
D1 D2 D1 D2 D1 D2 D1 D2 D1 D2 D1 D2
Dent[32]  13.6a     38a 0 0   0   0 0   0 81 76
British[33,36]     28a     46a    6.5a 13a 27   9  41  571 NS NS 35 33
Dutch[34,37]     24a     43a 4a 10a 11 37 3 30 43 47 45 47
Dutch - 15 yr[38]  22a  12a 21 29
Taiwanese[39,44]    7.3a  17.1a 0 0   3   1   11  131    50.6    40.3     53.6a     59.5a
Italian[35,43]    12 17.9 3    2.2      6.8      9.0     1.5      1.5    66.5    64.2
Table 1  The primary and revised results of prospective randomized trials comparing D1 to D2 dissection
aP < 0.05. 1Pancreato-splenectomy. RR: Relapse risk; OS: Overall survival; NS: Non-significant.
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with T3 tumor shows a survival difference favoring D2 
lymphadenectomy (25.9% vs 11.5%), and there is a 
trend towards a lower risk of gastric cancer­related death 
among patients having a D2 dissection with preservation 
of the spleen or pancreas and non-statistically significant 
improvement of survival for node­positive patients[40,45]. 
Unfortunately, the main problem of meta­analysis was 
that it was not possible to match patient groups for 
treatment with age, sex, type of gastrectomy, patho­
logical stage, tumor location, co­morbidity, treatment 
strategies, surgeon experience, hospital case volume and 
extent of LN dissection, all of which affect postoperative 
complications and overall survival rates[40]. 
Keeping this in mind, the comparison of oncological 
outcomes of D1 and D2 dissections in association with 
different T and N stages could be problematic due to 
the concept of stage migration. The reason for this is 
that a limited lymphadenectomy can not represent 
the adequate staging of LN involvement. Conversely, 
extended lymphadenectomy could improve stage­
specific survival due to the stage migration phenomenon. 
Furthermore, Xu et al[46]demonstrated that it is necessary 
to examine at least 16 LNs for accurate pathological 
examination of gastric cancer, even in node­negative 
gastric cancer patients[25], and Datta et al[47], who 
analyzed the data of more than 22000 patients found 
that the examination of 15 or more LN is a reproducible 
prognostic factor for gastric cancer outcomes in the 
United States and should continue to serve as a bench­
mark for the quality of care.
In addition to the quality of surgery, the pathologist 
plays a large role in the proper identification and exami-
nation of the extracted LN[48].
EXTENSION OF LYMPHADENECTOMY 
BEYOND SUGGESTED LIMITS
The latest issue of the Japanese Gastric Cancer Asso­
ciation treatment guideline contains the standard 
lymphadenectomies regarding the type of gastric 
resection: Total gastrectomy with D2: D1 (Nos.: 1­7) + 
Nos. 8a, 9, 10, 11p, 11d, 12a; distal gastrectomy with 
D2: D1 (Nos. 1, 3, 4sb, 4d, 5, 6, 7) + Nos. 8a, 9, 11p, 
12a; pylorus­preserving gastrectomy with D1+: D1 
(Nos. 1, 3, 4sb, 4d, 6, 7) + Nos. 8a, 9; and in proximal 
gastrectomy with D1+: D1(Nos. 1, 2, 3a, 4sa, 4sb, 7) + 
Nos. 8a, 9, 11p[49].
In the field of tumor-location specific LN involvement 
recent studies can be divided into 2 cohorts depend on 
the position of the gastric tumor (proximal vs middle 
and distal).
Proximal gastric cancer
The frequency of metastasis in station no.4d, 5 and 6 
LNs in patients with proximal gastric cancer is more than 
10%[14,50]. The incidence of station no.10 LN metastasis 
is 11.82% in upper third advanced gastric cancer (AGC). 
The estimated OS were 46% and 37% regarding station 
no.10 dissection or not, which was not statistically signi­
ficant. Authors suggest high­quality studies with larger 
sample sizes to determine the clinical significance of 
no.10 LN removal[51]. Following an 18 mo follow­up of 
108 patients Li et al[52] concluded that routine no.10 
lymphadenectomy may be unnecessary for advanced, 
upper third gastric cancer without serosal invasion, 
unless T3 tumors are located in the greater curvature.
Middle and distal gastric cancer
LN metastasis in station no.2 LNs from distal gastric 
cancer is only 1.0%, while the metastasis in station no.4 
LNs is more than 20%. Since station no.11p is imme­
diately adjacent to stations no.7 and no.9, in the case of 
distal gastric cancer, station no.11d should be preserved; 
however, both no.11p and no.11d stations should be 
removed in cases of proximal gastric cancer[14]. According 
to Japanese gastric cancer treatment, as station no.14v 
is closely adjacent to station no.6, station no.14v LNs 
should also be removed if suspicion of metastasis to the 
LNs in station no.6 arises[14,49].
As the LN metastasis rate in station no.7 was similar 
to that of perigastric LNs in 570 patients with advanced 
distal gastric tumor it is reasonable to include LNs in 
the no.7 station in the D1 LN dissection[53]. Evaluating 
LN involvement after total gastrectomy, Galizia found 
that the incidence of nodal involvement of stations 
no.10, no.11d, and no.12a was 5%, and the 5­year DFS 
rate was zero; they concluded that modified D2 lym­
phadenectomy confers the same oncologic adequacy 
as standard D2 lymphadenectomy, with a significant 
reduction of postoperative morbidity[54]. 
During investigation of LN involvement of the hepato­
duodenal ligament (HDLN) a logistic regression analysis 
showed that no.5 and no.12a LN metastases were 
associated with a 6.9 and 11.3 fold increase respec­
tively, for risk of no.12p and no.12b LN metastases. In 
addition, significant differences in 5-year OS of patients 
with and without no.12p and no.12b LN metastases 
were observed[55]. However, the clinical significance of 
removing these LN was not evaluated. Analyzing the data 
of 1872 patients, LN involvement in station no.12 was 
3.6% whereas HDLN metastasis was not a significant 
factor for survival in multivariate analysis and the 5­year 
survival rate of 41 patients with HDLN metastasis without 
distant metastasis at any other site was significantly 
higher than that among 120 patients with stage Ⅳ 
disease without HDLN metastasis. It is suggested that 
the inclusion of HDLN in the distant metastatic LN group 
in gastric cancer is inappropriate and that the seventh 
American Joint Committee on Cancer criteria for node 
grouping should be revised[56]. 
The incidence of no. 14v LN metastasis was 5.0% in 
1661 patients who underwent curative resection for middle 
or lower third gastric cancer. In clinical stages Ⅰ and 
Ⅱ, no.14v LN dissection did not affect overall survival; 
in contrast, no.14v LN dissection was an independent 
prognostic factor in patients with clinical stage Ⅲ/Ⅳ 
Tóth D et al . Clinical significance of lymphadenectomy
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gastric cancer[57].
Involvement of no.13 nodes is defined as M1 in the 
current version of the Japanese classification. However, 
excision of this LN may be an option in a potentially curative 
gastrectomy for tumors invading the duodenum[49].
Para-aortic nodal dissection 
The Japanese authors do not perform randomized 
trials comparing D1 and D2 dissection, because they 
have excellent operative and oncological outcomes 
with extended lymphadenectomy. The majority of trials 
with “super­extended” lymphadenectomy are being 
performed in Asia. The incidence of para­aortic lymph 
nodes (PALN) metastases was 8.5% in the JCOG 9501 
multi­institutional randomized trial, which proved that 
D2 lymphadenectomy plus para­aortic nodal dissection 
(PAND) did not increase the OS (70.3% vs 69.2%) 
or 5­year recurrence­free survival (61.7% vs 62.6%) 
in curable gastric cancer vs D2 lymphadenectomy[58]. 
Robertson strengthened this finding in a prospective 
randomized trial from Hong Kong[59]. Junfeng et al[60] 
found 6 risk factors to predict the involvement of PALN: 
Tumor in the upper third, tumor size over 5 cm, tumor 
penetrating deeper than T2, tumor in stage N2 and N3, 
tumor regarded as the poorly differentiated type and the 
Borrman 3, 4 type by macroscopic classification. Addi­
tionally, the metastasis of lower lymph nodal stations 
may be predictors of the positive PALN especially no.1, 
no.3, no.7 and no.9 stations which evidently had higher 
odd ratios than the others[60]. de Manzoni et al[61] did not 
find a significant difference in the cumulative incidence 
of recurrence between D2 and D3 lymphadenectomy 
in the analysis of 568 patients. The risk of recurrence 
was higher after D3 than after D2 (45.1% vs 35.3%, 
P = 0.078) in the intestinal histotype while the pattern 
was reversed in the mixed/diffuse histotype (48.3% vs 
61.5%,  P = 0.084)[61].
In overall 5­year survival Zhang et al[62] could not 
demonstrate a significant difference between patients 
underwent D2 plus PAND surgery and those underwent 
D2 surgery. He suggests that this “over­extended” dissec­
tion should only be recommended for T3­4 and N2 stage 
gastric tumor and should not be utilized for EGC and total 
gastrectomy[62].
So, the D2 lymphadenectomy is the gold standard 
in R0 resection by the Japanese[49] and European guide­
lines[27].
The American NCCN guidelines recommend a D1+ 
or a modified D2 LN dissection, the latter performed 
by experienced surgeons in high­volume centers[27,63]. 
To support this, the deployment of centralization and 
implementation of national clinical guidelines in Denmark 
resulted in a decrease in mortality from 8.2% to 2.4% 
and the proportion of patients with at least 15 LNs 
removed has increased from 19% to 76%[64]. 
MARUYAMA COMPUTER PROGRAM 
The Maruyama computer program (MCP) was developed 
and first published in 1989[65]. It was later improved as 
the Windows­based program WinEstimate v. 2.5 using 
a database of 4302 primary gastric cancer patients 
treated at the National Cancer Center Hospital in Tokyo 
between 1968 and 1989[66,67]. This program calculates 
the expectation (%) of lymph­node involvement in sta­
tion No. 1­16. The calculation required the following 
prognostic factors: Age, gender, position of the tumor, 
Bormann’s classification or EGC classification, depth of 
infiltration and histological type (Figure 1)[68]. MCP was 
validated in Japanese patients and the program was able 
to predict LN involvement in 94%[69]. In the European 
region the accuracy of MCP was 91% in Slovenian 
patients[67] and 83.4% for stations 1 to 6 and 81.6% for 
stations 7 to 12 in Italian patients[70]. The sensitivity for 
LN detection was high (97%­100%) in a German study 
of 222 patients but a specificity as low as 20% was found 
for perigastric LNs (stations 1 to 6)[68,71]. Similarly in an 
Italian study, where the sensitivity increased to 100% 
with a lower cut­off level, the specificity decreased to 
26%. Better prediction of LN metastases may be feasible 
with the artificial neural network using the following 
parameters: Bormann classification, depth of tumor 
infiltration, size, location of tumor, and LN metastases 














Figure 1  Prediction of lymph node involvement by the Maruyama computer program in a 65-year-old male patient. The tumor histology was well differentiated 
adenocarcinoma, showing muscular mucosa involvement, early cancer type 2B. The lesion was found in the anterior wall in the lower third of the stomach and had a 
maximal diameter of 30 mm.
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93%[72]. 
Our study demonstrated a similar degree of reliability 
of MCP to those cited above, with 90.2% of sensitivity, 
63.3% of specificity and 78.4% of accuracy. The rate of 
false negatives was 9.8%[73]. These studies demonstrate 
that the results of the computerized prediction of LN 
metastases are superior to those of the standard pre­
operative imaging techniques. 
Another advantage of the MCP is that it can deter­
mine long term oncological results. Hundahl defined 
the Maruyama Index (MI) at first in 2002 as a measure 
of unresected regional nodal disease in gastric cancer 
using the data of the Intergroup 0116 trial and he 
proved it is an independent predictor of survival[74,75]. 
Peeters et al[76] reanalyzed the data of the Dutch D1­D2 
trial using univariate and multivariate analyses and 
showed that the MI is an independent predictor of 
overall survival (P = 0.016, HR = 1.45) and relapse risk 
(P = 0.010, HR = 1.72). It was concluded that the MI 
is a quantitative yardstick for assessing the adequacy 
of lymphadenectomy in gastric cancer patients[75,76]. 
Later, Hundahl evaluated autopsy findings from the 
Dutch D1­D2 trial and showed that MI < 5 or a low MI 
for surgery is associated with enhanced regional control 
and survival[76,77]. Dikken et al[78] proved the prognostic 
significance of low MI in a 2-year survival rate (82% vs 
59%), as did Sachdev, who demonstrated that lower MI 
correlated with better survival, as a continuous (P < 0.02) 
and categorical (P < 0.04) variable[79].
Overall these results suggest that a Maruyama Index 
less than 5 has a better impact on survival, than D­level 
guided surgery. For these reasons, the preoperative 
application of MCP is recommended routinely, with an aim 
to perform “low Maruyama Index surgery”. In addition, 
the application of MCP to predict LN involvement can 
influence the indication for neoadjuvant chemo-therapy, 
and furthermore a “high Maruyama Index” could indicate 
the necessity for postoperative oncological treatment.
SENTINEL LYMPH NODE BIOPSY 
While the MCP calculates the probability of LN invo­
lvement preoperatively, the concept of sentinel lymph 
node biopsy (SNB) can determine the existence of LN 
metastases intraoperatively. The first potentially affected 
LN, the sentinel lymph node (SLN), reliably reflects the 
status of the nodes in the second and third line, which 
is supported by data of numerous publications. If the 
SLN contains tumor deposit(s), extended dissection 
is warranted, but if findings are negative, the patient 
could be spared additional complications associated with 
extended dissection. However, the method of dye/tracer 
injection and the tracer’s selection is controversial. Some 
authors use dye alone (patent blue, indocyanine green, 
isosulfan blue)[11,80­82], Kitagawa et al[83] handle 99m Tc 
colloid, and Aikou et al[84] uses the combination of these 
tracers. The latest systematic review concluded that the 
SLN’s identification rate is the same with the dual or 
single mapping method[85]. It is eminent that body­mass 
index (BMI) affects the sentinel LN detection rate[86]. 
The Hungarian study proved that the identification of 
sentinel LNs in obese patients can be difficult owing to 
the feathering of blue dye in the fatty tissues[11]. This 
was concluded as the only patient in whom marking did 
not occur had a BMI significantly higher than average 
(26.8 vs 22.8)[11]. Then again, the application of blue 
dye for SNB has a beneficial side effect, as it significantly 
increased the number of harvested LN and the ratio of 
the number of the harvested LN per time[87]. To avoid 
quick dispersal to multiple LNs Kong applied ICG/poly­
γ­glutamic acid complex, which remained longer than 
diluted ICG in animal models[88].
Yaguchi, Lee and Tóth have compared the subserosal 
to the submucosal labeling method (Figures 2 and 3) 
without any significant difference and they suggest the 
endoscopic injection of a tracer in cases of non­palpable 
tumors and/or laparoscopic procedures[89­91].
The cardinal problem in the SNB concept is the intrao­
perative false negative rate. The JCOG 0302 trial called 
attention to the importance of the learning curve and the 
inadequacy of the pick­up method. The demand for only 
five patients per institute provided an insufficient learning 
period which presented a 46% false negative rate[92]. 
Lee et al[93] proved that the removal of entire nodal 
basins can significantly decrease this rate against the 
pick­up method, and Kumagai et al[94] called attention to 
the opportunity of introducing the one­step nucleic acid 
Figure 2  Sentinel lymph node mapping following submucosal marking by 
an endoscopist.
Figure 3  Subserosal marking by a surgeon.
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amplification test for the intraoperative diagnosis of LN 
metastasis with similar results to postoperative 2­mm­
interval histological examination. 
Miyashiro et al[95] demonstrated that an extensive 
surgical experience is necessary for application of SNB 
concept and standardization of SLN mapping technique, 
using improved tracer, and guideline to evaluate the 
positiveness of SLN specimen should be planned to 
incorporate SNB in routine practice[96]. Recent studies 
and the latest meta­analysis of SLN mapping have 
shown a high detection rate (93.7%) and an accuracy 
of 92%[97] and suggest that the SNB concept could be 
suitable for tumors following endoscopic resection[98] and 
could represent a new era of sentinel node navigation 
surgery in EGC[99,100]. Moreover, its success rate did not 
correlate to tumor grade[101].
Based on the results of the largest prospective multi­
center trial from Japan with an identification rate of 
97.5% and an accuracy of 99%[102], a phase Ⅲ multi­
center trial for individualized surgery for EGC based 
on SLN mapping has been commenced in the Eastern 
Asian countries. The long­term results of these studies 
will be available between 2018 and 2020.
CONCLUSION
The latest RCT comparing D1 and D2 dissections re­
presents a higher surgical quality (more contamination, 
less non­compliance, low morbidity and mortality rate) 
than previous trials[43]. This could lead to a trend towards 
the execution of the less limited D1 lymphadenectomy 
for more experienced and well­trained surgeons, and 
hopefully the results of western surgeons will achieve a 
level similar to those of the Asian surgical outcomes in 
the near future.
On the other hand, the era of multimodal treatment 
and the increase in elderly patients with serious com­
orbidities indicates the necessity of a stage­ and 
patient­adapted, individualized surgery in gastric 
cancer. It was conceived at an expert panel, also: “A 
D2 lymphadenectomy is preferred for curative­intent 
resection in advanced, non­metastatic gastric cancer; 
in patients with EGC or substantial comorbidities, a 
D1 lymphadenectomy is more appropriate”[103]. The 
Japanese guidelines enclose that the AGC should be 
treated with D2 lymphadenectomy. D1 or D1+ should 
be recommended as a choice for EGC. D1+ can be an 
alternate for D2 in high­risk patients[104]. Inokuchi et al[105] 
suggested that the presence of heart or liver disease 
is a significant risk factor for postoperative morbidity 
in patients who undergo laparoscopic gastrectomy. 
Although it did not reduce complications, insufficient 
LN dissection (for example, D1+ for advanced gastric 
cancer) might be permissible in high­risk patients as 
it had no negative impact on gastric cancer­specific 
survival. More accurate stage­adapted surgery could be 
performed using the MCP and SNB in parallel fashion.
It is generally accepted that metastases in the SLNs 
warrant a D2 lymphadenectomy. The authors analyzed 
the relevance of MCP in sentinel node positive patients 
in an earlier study[73]; while the efficiency of SNB 
method is superior to MCP, the positive predictive value 
of MCP and SNB was proven equivalent in the sentinel 
node positive group and the accuracy of MCP in these 
cohort of patients was 10% higher. For these reasons it 
would be interesting to find the appropriate combination 
of these techniques in the future and we suggest using 
them simultaneously in the operating room. 
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